Currently, ophthalmologists favor using intravitreal anti-vascular endothelial growth factor (anti-VEGF) to treat various ischemic retinal diseases such as DR and retinal vein occlusions, unless there is a contraindication or patient refusal [8]. This evidence concerns the gene VEGFA and retinal vein occlusion.